Core Framework & Diagram The Birth of CAR-T (From Failure to Breakthrough)

Both are immunotherapy, but mechanisms are completely different. Checkpoint inhibitors 'release brakes,' letting patients' existing T cells reactivate; CAR-T 'customizes weapons,' engineering T cells before sending them back to specifically hunt a target. The former has wider applicability but higher requirements for tumor immunogenicity; the latter has precise targeting but complex manufacturing, extremely high cost, and currently mainly effective in blood tumors. Both can be used in combination.

Severity ranges from mild fever (Grade 1, no intervention needed) to life-threatening multi-organ failure (Grade 4, requiring intensive care). Most patients' CRS can be managed with supportive care and tocilizumab, but about five to ten percent of patients develop Grade 3–4 severe CRS. Neurotoxicity (ICANS) is another important side effect, manifesting as confusion and speech impairment, with brain edema in severe cases. This is why CAR-T treatment must be conducted at specially certified medical centers.

Theoretically yes. CAR-T cells can form memory in the body, providing durable protection. But in practice, some patients still relapse after initial complete remission, reasons including: tumor cells downregulating CD19 and other target antigen expression (antigen escape), or CAR-T cells exhausting over time in the body. For antigen escape, researchers are developing dual-target CAR-T simultaneously targeting CD19 and CD22; for exhaustion, researchers are designing CAR-T with 'anti-exhaustion' epigenetic characteristics.

Currently far less effective in solid tumors than blood tumors. Main challenges: solid tumors lack ideal specific targets (most candidate targets also expressed in normal tissue); tumor microenvironment immunosuppression (large amounts of TGF-β, PD-L1, Treg suppress CAR-T activity); and physical barriers to CAR-T penetrating solid tumors (dense extracellular matrix). Current research focuses on HER2, GD2, EGFR targets, and armored CAR-T and CAR-T + oncolytic virus combination strategies, but large-scale clinical breakthroughs haven't yet emerged.

In the United States, Kymriah and Yescarta are priced at approximately $370,000 and $370,000–470,000 respectively (not including hospitalization and management fees), making CAR-T one of the most expensive single treatments to date. Some countries (including China, some EU countries) have insurance coverage plans, or pharmaceutical companies offer outcomes-based pricing (no charge if ineffective). For some relapsed/refractory patients, even considering costs, CAR-T may be the only option to extend life — this pricing has generated extensive discussion about medical equity.